Tags: Inhaler Approved for Cystic Fibrosis Patients

Inhaler Approved for Cystic Fibrosis Patients

Tuesday, 02 Apr 2013 10:38 AM

The TOBI Podhaler (tobramycin inhalation powder) has been approved by the U.S. Food and Drug Administration to treat cystic fibrosis patients infected with Pseudomonas aeruginosa, a bacterium that can damage the lungs.
 
Cystic fibrosis, affecting about 30,000 people in the United States, causes production of thick, sticky mucus that builds up in the lungs. This can lead to chronic bacterial infections, the FDA said in a news release.
 
The TOBI Podhaler, used twice daily, was evaluated in clinical trials involving 95 adults and children six years and older with cystic fibrosis. The most common side effects included cough, coughing up blood, shortness of breath, fever, mouth and throat pain, changes in voice and headache.
 
The antibiotic inhaler is marketed by Novartis, based in East Hanover, N.J.

© HealthDay

   
1Like our page
2Share
FDA-Approved-Drugs
The TOBI Podhaler(tobramycin inhalation powder) has been approved by the U.S. Food andDrug Administration to treat cystic fibrosis patients infected with Pseudomonas aeruginosa.
Inhaler Approved for Cystic Fibrosis Patients
127
2013-38-02
Tuesday, 02 Apr 2013 10:38 AM
Newsmax Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved